Cannabis Science Issues First Market and Revenue Guidance in Regards to the Top 10 Cancer Formulations the Company Intends Focus on over Next Ten Years

December 14, 2011

DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB: CBIS.ob), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that we have a variety of cannabis-based formulations that target critical ailments worldwide. Illnesses ranging from cancer to pain management give the company a large market and revenue base potential. As outlined on the company website www.cannabisscience.com our initial target of self-administered cancer formulations proves to be the fastest to market application as prompted by recent successful cannabis-based treatments outlined in earlier press releases issued by the Company.

Marketresearch.com says cancer is the second-leading cause of death in the United States, and the world market for cancer therapy is growing at a brisk double-digit pace of over 10% per year, with total treatments revenues surpassing $40 billion this year in the USA alone.

Current market research and analysis shows Cannabis Science in a position to capitalize on the current annual cancer revenues at the low end of scale at approximately 1% market share giving the company a projected $400 million total revenues per year less associated costs.

The Top Ten Cancers and their respective markets Cannabis Science intends to focus on in regards to their formulations are Basal Cell Carcinoma and Squamous Cell Carcinoma (Skin Cancers), Ductal Carcinoma (Breast Cancer), Colon Cancer, Glioma (Brain Tumor), Lung Cancer, Multiple Myeloma (Bone Marrow), Ovarian Cancer, Pheochromocytoma (Adrenal Gland), and Prostate Cancer.

Cannabis Science estimates that there are over 7 million patients who suffer from these cancers in the USA alone and who could potentially benefit from the Cannabis Science Based Extract formulations as they initially become available in states with appropriate medical marijuana laws.

Robert Kane, Investor Relations Manager stated, “Our primary goals here at Cannabis Science in regards to increasing shareholder value started with more efficient communication and increased guidance in regards to the revenue and earnings potential of their business model. With the establishment of the Facebook and Twitter accounts, and the incredible support they have given me, it has allowed Cannabis Science to answer and respond to shareholder inquiries much more efficiently than in the past. Now, with this release of this market and revenue guidance, I applaud Dr. Melamede and his team for accomplishing these goals, and doing it so in such an efficient manner. Cannabis Science vigilantly continues to work on their projections and forecasts of their products for potential conditions that Cannabis Science will focus on in the future these projections and forecasts include different global geographical market and different medical conditions going forward over the next ten years. I look forward to sharing that guidance as it approved.”

Dr. Robert Melamede, President of Cannabis Science stated, “This information contained in this guidance demonstrates that we have a viable business model. We will generate revenues from our strategic alliance with MEDBOX, as well as from our Cannabis Extract Based Formulations. These revenue streams, as well as additional ones that we are currently working on, will allow us to fund our FDA efforts on a national level while we test and develop products on the medical marijuana state level.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek, "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Robert Kane, 561-234-6929
Investor Relations
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
or
Dr. Robert Melamede, President
www.cannabisscience.com
This e-mail address is being protected from spambots. You need JavaScript enabled to view it